ArticleThe Journal of clinical investigation2013
ADCK4 "reenergizes" nephrotic syndrome.
Article in The Journal of clinical investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- The ADCK Kinase Family: Key Regulators of Bioenergetics and Mitochondrial Function and Their Implications in Human Cancers.International journal of molecular sciences · 2025Review
- Nucleoporin-associated steroid-resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2025Review
- Article
- Clinical features and gene variation analysis of COQ8B nephropathy: Report of seven cases.Frontiers in pediatrics · 2022Article
- Mitochondrial Disease and the Kidney With a Special Focus on CoQKidney international reports · 2020Review
- Transcription factor Kruppel-like factor 5 positively regulates the expression of AarF domain containing kinase 4.Molecular biology reports · 2020Article
- Early-onset COQ8B (ADCK4) glomerulopathy in a child with isolated proteinuria: a case report and literature review.BMC nephrology · 2020Review
- Understanding the kidney one cell at a time.Kidney international · 2019Review
- Single-cell transcriptomics of the mouse kidney reveals potential cellular targets of kidney disease.Science (New York, N.Y.) · 2018Article
- Akt2 causes TGFβ-induced deptor downregulation facilitating mTOR to drive podocyte hypertrophy and matrix protein expression.PloS one · 2018Article
- Steroid-resistant nephrotic syndrome caused by co-inheritance of mutations atIntractable & rare diseases research · 2017Article
- Review
- Early-onset of ADCK4 glomerulopathy with renal failure: a case report.BMC medical genetics · 2017Article
- The long noncoding RNA Tug1 connects metabolic changes with kidney disease in podocytes.The Journal of clinical investigation · 2016Article
- The next generation of therapeutics for chronic kidney disease.Nature reviews. Drug discovery · 2016Review
- Mitochonic Acid 5 Binds Mitochondria and Ameliorates Renal Tubular and Cardiac Myocyte Damage.Journal of the American Society of Nephrology : JASN · 2016Article
- Podocytes: the Weakest Link in Diabetic Kidney Disease?Current diabetes reports · 2016Review
- Pharmacological targeting of GSK3β confers protection against podocytopathy and proteinuria by desensitizing mitochondrial permeability transition.British journal of pharmacology · 2015Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Steroid-resistant nephrotic syndrome has a poor prognosis and often leads to end-stage renal disease development. In this issue of the JCI, Ashraf and colleagues used exome sequencing to identify mutations in the aarF domain containing kinase 4 (ADCK4) gene that cause steroid-resistant nephrotic syndrome. Patients with ADCK4 mutations had lower coenzyme Q10 levels, and coenzyme Q10 supplementation ameliorated renal disease in a patient with this particular mutation, suggesting a potential therapy for patients with steroid-resistant nephrotic syndrome with ADCK4 mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.